Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report

Mariona Riudavets; Arshid Azarine; Sondes Smaali; Young Wouk Kim; Vincent Thomas de Montpréville; Alina Miruna Grecea; Charles Naltet; Annas Gazzah; David Planchard

doi:10.1016/j.jtocrr.2022.100432

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report

Mariona Riudavets, Arshid Azarine, Sondes Smaali, Young Wouk Kim, Vincent Thomas de Montpréville, Alina Miruna Grecea, Charles Naltet, Annas Gazzah, David Planchard

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

3 Citations (Scopus)

Résumé

Antibody-drug conjugates targeting receptor tyrosine-protein kinase erbB-2 (ERBB2, HER2) have emerged as promising targeted options for HER2-mutant NSCLC. Among antibody-drug conjugates targeting HER2, trastuzumab deruxtecan was found to have the most impressive efficacy and is a potential new standard of care. Drug-related interstitial lung disease remains a serious unpredictable identified risk for patients treated with trastuzumab deruxtecan, requiring careful monitoring and multidisciplinary management. We report the first two cases of drug-related cardiotoxicity with acute myocarditis that developed after the first trastuzumab deruxtecan cycle. Routine cardiovascular risk screening is advisable, with close collaboration between cardiology specialists and oncologists.

langue originale	Anglais
Numéro d'article	100432
journal	JTO Clinical and Research Reports
Volume	3
Numéro de publication	12
Les DOIs	https://doi.org/10.1016/j.jtocrr.2022.100432
état	Publié - 1 déc. 2022

Accès au document

10.1016/j.jtocrr.2022.100432

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{6de600946a58430f9bc2e37ee8e9eaf4,

title = "Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report",

abstract = "Antibody-drug conjugates targeting receptor tyrosine-protein kinase erbB-2 (ERBB2, HER2) have emerged as promising targeted options for HER2-mutant NSCLC. Among antibody-drug conjugates targeting HER2, trastuzumab deruxtecan was found to have the most impressive efficacy and is a potential new standard of care. Drug-related interstitial lung disease remains a serious unpredictable identified risk for patients treated with trastuzumab deruxtecan, requiring careful monitoring and multidisciplinary management. We report the first two cases of drug-related cardiotoxicity with acute myocarditis that developed after the first trastuzumab deruxtecan cycle. Routine cardiovascular risk screening is advisable, with close collaboration between cardiology specialists and oncologists.",

keywords = "Antibody drug conjugates, Cardiotoxicity: Case Report, HER2 mutation, Non–small cell lung cancer, Trastuzumab deruxtecan",

author = "Mariona Riudavets and Arshid Azarine and Sondes Smaali and Kim, {Young Wouk} and {Thomas de Montpr{\'e}ville}, Vincent and Grecea, {Alina Miruna} and Charles Naltet and Annas Gazzah and David Planchard",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2022",

month = dec,

day = "1",

doi = "10.1016/j.jtocrr.2022.100432",

language = "English",

volume = "3",

journal = "JTO Clinical and Research Reports",

issn = "2666-3643",

number = "12",

}

TY - JOUR

T1 - Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan

T2 - A Case Report

AU - Riudavets, Mariona

AU - Azarine, Arshid

AU - Smaali, Sondes

AU - Kim, Young Wouk

AU - Thomas de Montpréville, Vincent

AU - Grecea, Alina Miruna

AU - Naltet, Charles

AU - Gazzah, Annas

AU - Planchard, David

PY - 2022/12/1

Y1 - 2022/12/1

N2 - Antibody-drug conjugates targeting receptor tyrosine-protein kinase erbB-2 (ERBB2, HER2) have emerged as promising targeted options for HER2-mutant NSCLC. Among antibody-drug conjugates targeting HER2, trastuzumab deruxtecan was found to have the most impressive efficacy and is a potential new standard of care. Drug-related interstitial lung disease remains a serious unpredictable identified risk for patients treated with trastuzumab deruxtecan, requiring careful monitoring and multidisciplinary management. We report the first two cases of drug-related cardiotoxicity with acute myocarditis that developed after the first trastuzumab deruxtecan cycle. Routine cardiovascular risk screening is advisable, with close collaboration between cardiology specialists and oncologists.

AB - Antibody-drug conjugates targeting receptor tyrosine-protein kinase erbB-2 (ERBB2, HER2) have emerged as promising targeted options for HER2-mutant NSCLC. Among antibody-drug conjugates targeting HER2, trastuzumab deruxtecan was found to have the most impressive efficacy and is a potential new standard of care. Drug-related interstitial lung disease remains a serious unpredictable identified risk for patients treated with trastuzumab deruxtecan, requiring careful monitoring and multidisciplinary management. We report the first two cases of drug-related cardiotoxicity with acute myocarditis that developed after the first trastuzumab deruxtecan cycle. Routine cardiovascular risk screening is advisable, with close collaboration between cardiology specialists and oncologists.

KW - Antibody drug conjugates

KW - Cardiotoxicity: Case Report

KW - HER2 mutation

KW - Non–small cell lung cancer

KW - Trastuzumab deruxtecan

UR - http://www.scopus.com/inward/record.url?scp=85143174817&partnerID=8YFLogxK

U2 - 10.1016/j.jtocrr.2022.100432

DO - 10.1016/j.jtocrr.2022.100432

M3 - Article

AN - SCOPUS:85143174817

SN - 2666-3643

VL - 3

JO - JTO Clinical and Research Reports

JF - JTO Clinical and Research Reports

IS - 12

M1 - 100432

ER -